This clinical trial, sponsored by Tongji Hospital, aims to evaluate the efficacy of oral diammonium glycyrrhizinate in enhancing the therapeutic outcomes of CAR-T cell therapy for patients with large B-cell lymphoma. The study addresses critical issues such as reducing the incidence and severity of CRS, a significant adverse effect associated with CAR-T therapies. If successful, this intervention could position diammonium glycyrrhizinate as a valuable adjunctive treatment in the CAR-T landscape, potentially expanding its market appeal and providing a competitive edge against existing supportive care options. The trial's outcomes may also influence future treatment protocols and reimbursement strategies, highlighting the need for diligence in assessing market entry and partnership opportunities.